|
|
Volumn 13, Issue 5, 2002, Pages 777-780
|
|
Phase II study of XR5000 (DACA) administered as a 120-h infusion in patients with recurrent glioblastoma multiforme
a
|
|
Author keywords
Chemotherapy; Glioblastoma multiforme; Phase II
|
|
Indexed keywords
ACRIDINE DERIVATIVE;
DACA, ACRIDINE;
N (2 DIMETHYLAMINOETHYL) 4 ACRIDINECARBOXAMIDE;
STEROID;
XR 5000;
ADULT;
AGED;
ARTICLE;
BRAIN TUMOR;
CANCER STAGING;
CLINICAL TRIAL;
COMPARATIVE STUDY;
DOSE RESPONSE;
DRUG ADMINISTRATION;
FEMALE;
FOLLOW UP;
GLIOBLASTOMA;
HUMAN;
INTRAVENOUS DRUG ADMINISTRATION;
MALE;
MIDDLE AGED;
MORTALITY;
PATHOLOGY;
PHASE 2 CLINICAL TRIAL;
SURVIVAL;
TREATMENT OUTCOME;
TUMOR RECURRENCE;
AXILLARY VEIN;
BLOOD TOXICITY;
CANCER PAIN;
CANCER RECURRENCE;
CANCER SIZE;
CENTRAL VEIN;
CLINICAL ARTICLE;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DISEASE SEVERITY;
DRUG EFFICACY;
DRUG INFUSION;
DRUG RESPONSE;
DRUG TOLERABILITY;
FEVER;
HEALTH STATUS;
NEUTROPENIA;
PERFORMANCE;
PRIORITY JOURNAL;
RIGOR;
THORAX PAIN;
VEIN THROMBOSIS;
VOMITING;
ACRIDINES;
ADULT;
AGED;
BRAIN NEOPLASMS;
DOSE-RESPONSE RELATIONSHIP, DRUG;
DRUG ADMINISTRATION SCHEDULE;
FEMALE;
FOLLOW-UP STUDIES;
GLIOBLASTOMA;
HUMANS;
INFUSIONS, INTRAVENOUS;
MALE;
MIDDLE AGED;
NEOPLASM RECURRENCE, LOCAL;
NEOPLASM STAGING;
SURVIVAL ANALYSIS;
TREATMENT OUTCOME;
COMPARATIVE STUDY;
HUMAN;
MIDDLE AGE;
SUPPORT, NON-U.S. GOV'T;
|
|
EID: 0035985319
PISSN: 09237534
EISSN: None
Source Type: Journal
DOI: 10.1093/annonc/mdf121 Document Type: Article |
|
Times cited : (27)
|
|
References (16)
|
